CN102170879B - 调控释放制剂及其应用方法 - Google Patents

调控释放制剂及其应用方法 Download PDF

Info

Publication number
CN102170879B
CN102170879B CN200980136417.8A CN200980136417A CN102170879B CN 102170879 B CN102170879 B CN 102170879B CN 200980136417 A CN200980136417 A CN 200980136417A CN 102170879 B CN102170879 B CN 102170879B
Authority
CN
China
Prior art keywords
retigabine
preparation
formulations
formulation
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980136417.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102170879A (zh
Inventor
比利安娜·纳吉松巴蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch Health Americas Inc
Original Assignee
Valeant Pharmaceuticals International Inc USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41550741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102170879(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valeant Pharmaceuticals International Inc USA filed Critical Valeant Pharmaceuticals International Inc USA
Publication of CN102170879A publication Critical patent/CN102170879A/zh
Application granted granted Critical
Publication of CN102170879B publication Critical patent/CN102170879B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200980136417.8A 2008-07-18 2009-07-17 调控释放制剂及其应用方法 Expired - Fee Related CN102170879B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8216208P 2008-07-18 2008-07-18
US61/082,162 2008-07-18
PCT/US2009/051052 WO2010009433A1 (en) 2008-07-18 2009-07-17 Modified release formulation and methods of use

Publications (2)

Publication Number Publication Date
CN102170879A CN102170879A (zh) 2011-08-31
CN102170879B true CN102170879B (zh) 2014-03-05

Family

ID=41550741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980136417.8A Expired - Fee Related CN102170879B (zh) 2008-07-18 2009-07-17 调控释放制剂及其应用方法

Country Status (16)

Country Link
US (1) US20100120906A1 (https=)
EP (1) EP2318001A4 (https=)
JP (1) JP2011528666A (https=)
KR (1) KR20110052641A (https=)
CN (1) CN102170879B (https=)
AU (1) AU2009270768A1 (https=)
BR (1) BRPI0916000A2 (https=)
CA (1) CA2731008A1 (https=)
CL (1) CL2011000109A1 (https=)
CO (1) CO6351716A2 (https=)
EA (1) EA201170230A1 (https=)
IL (1) IL210683A0 (https=)
MX (1) MX2011000636A (https=)
NZ (1) NZ590885A (https=)
WO (1) WO2010009433A1 (https=)
ZA (1) ZA201102518B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009013613A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013612A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
MX350056B (es) 2009-11-03 2017-08-25 Lupin Ltd Formulacion de liberacion modificada de lacosamida.
JP2013517315A (ja) 2010-01-20 2013-05-16 グラクソ グループ リミテッド 新規組成物
EP2525660A4 (en) * 2010-01-20 2013-08-07 Valeant Pharmaceuticals Int FORMULATION WITH MODIFIED RELEASE AND USE METHOD
WO2012098075A1 (en) 2011-01-18 2012-07-26 Glaxo Group Limited Process for the preparation of retigabine
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
CN109069480A (zh) 2015-12-30 2018-12-21 阿达玛斯医药公司 用于治疗与癫痫相关的病症的方法和组合物
CR20220313A (es) * 2019-12-02 2022-10-31 Xenon Pharmaceuticals Inc Formulación pediátrica de liberación inmediata del abridor de canales de potasio ezogabina
MX2023010976A (es) * 2021-03-19 2023-12-07 Xyzagen Inc Profármacos de abridores de canales kv7.

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) * 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
JP2000086509A (ja) * 1998-09-14 2000-03-28 Taisho Yakuhin Kogyo Kk ソファルコン含有製剤の製造方法
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
EP1200086A4 (en) * 1999-08-04 2009-05-27 Icagen Inc THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
CN1212831C (zh) * 2000-03-08 2005-08-03 Awd.药品股份有限两合公司 药物制剂
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes
AU2256702A (en) * 2000-12-01 2002-06-11 Kyowa Hakko Kogyo Kk Composition improved in solubility or oral absorbability
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US20020183395A1 (en) * 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
KR100425226B1 (ko) * 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
GB0120835D0 (en) * 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1524981B1 (en) * 2002-07-29 2009-03-11 Glaxo Group Limited Sustained release formulations comprising lamotrigine
AU2003272489B2 (en) * 2002-09-17 2008-11-13 Wyeth Granulated formulation of the rapamycin ester CCI779
JP2004131393A (ja) * 2002-10-08 2004-04-30 Kowa Co 易溶出性製剤
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
NZ546183A (en) * 2003-09-26 2011-04-29 Alza Corp Controlled release formulations exhibiting an ascending rate of release
GB0324574D0 (en) * 2003-10-21 2003-11-26 Glaxo Group Ltd Novel compositions
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
WO2006044202A2 (en) * 2004-10-19 2006-04-27 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US20100285123A1 (en) * 2005-06-20 2010-11-11 Rudresha Korlakunte Virupakshalah Prasad Controlled Release Dosage Formulation of Duloxetine
CN101868239B (zh) * 2006-01-05 2015-06-10 伊森舍丽斯有限公司 钾atp通道开放剂的盐及其用途
US8558470B2 (en) * 2006-01-20 2013-10-15 Point Somee Limited Liability Company Adaptive current regulation for solid state lighting
USD601689S1 (en) * 2006-05-12 2009-10-06 Glaxo Group Limited Pharmaceutical tablet
CN101578259A (zh) * 2006-11-28 2009-11-11 威朗国际制药公司 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物

Also Published As

Publication number Publication date
MX2011000636A (es) 2011-08-03
US20100120906A1 (en) 2010-05-13
CO6351716A2 (es) 2011-12-20
IL210683A0 (en) 2011-03-31
EP2318001A4 (en) 2013-02-20
NZ590885A (en) 2013-01-25
AU2009270768A1 (en) 2010-01-21
BRPI0916000A2 (pt) 2019-09-24
KR20110052641A (ko) 2011-05-18
JP2011528666A (ja) 2011-11-24
ZA201102518B (en) 2012-06-27
CA2731008A1 (en) 2010-01-21
EP2318001A1 (en) 2011-05-11
CN102170879A (zh) 2011-08-31
CL2011000109A1 (es) 2011-11-25
EA201170230A1 (ru) 2011-08-30
WO2010009433A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
CN102170879B (zh) 调控释放制剂及其应用方法
US20230081113A1 (en) Modified release preparations containing oxcarbazepine and derivatives thereof
CN102946869B (zh) γ-羟基丁酸的速释制剂及剂型
US20100323016A1 (en) Modified release formulation and methods of use
JP2006507277A (ja) ２４時間有効な持続放出トラマドール製剤
EA031719B1 (ru) Оральные составы деферазирокса
US20080220060A1 (en) Gastroretentive Formulations and Manufacturing Process Thereof
WO2008064202A2 (en) Modified-release formulations of calcium receptor-active compounds
US20230240999A1 (en) Novel fine particle coating (drug-containing hollow particle and method for manufacturing same)
AU2021235395B2 (en) Controlled release formulations comprising Drotaverine or salt thereof
JP2007530693A (ja) ６−メルカプトプリンの遅効性製剤
EP4424303A1 (en) Lenvatinib composition with improved bioavailability
CA3238807A1 (en) Controlled release formulations of flavoxate and process for preparation thereof
JP7330948B2 (ja) トシル酸スプラタストを含む組成物
WO2020055359A2 (en) Oral dosage form of sorafenib tosylate
US20250170065A1 (en) Therapeutic compounds, formulations, and use thereof
CN101031290B (zh) 改良释放的莫达非尼药物组合物
US20100323015A1 (en) Modified release formulation and methods of use
EA052180B1 (ru) Терапевтические соединения, составы и их применение
US20210346303A1 (en) Coating method
CN1942175B (zh) 24小时有效的曲马多缓释制剂
US20200215002A1 (en) Pharmaceutical compositions comprising cinacalcet hydrochloride and one or more binders
EP2525660A1 (en) Modified release formulation and methods of use
HK1124762A1 (en) Neramexane modified release matrix tablet
HK1124762B (en) Neramexane modified release matrix tablet

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140305

Termination date: 20140717

EXPY Termination of patent right or utility model